Tab. 4.
Anticancer selectivity pattern of the most active compounds at the GI50 (μM) and TGI (μM) levels.
| Cancer type | GI50, | μMa | SI(GI50)a | TGI, μMa | SI(TGI)a | |||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| IIa | IIb | IIa | IIb | IIa | IIb | IIa | IIb | |
| Leukemia | 1.89 | 3.73 | 2.40 | 8,00 | 5.35 | >100 | 12.38 | 0.99 |
| 2.97 | 3.61 | 2.31 | 13.6 | 15.30 | >100 | 5.14 | 1.00 | |
| NSC lung cancer | 3.65 | 49.77 | 1.24 | 0.60 | 90.59 | >100 | 0.76 | 0.99 |
| 10.49 | 52.07 | 0.66 | 0.95 | 87.02 | >100 | 0.89 | 1.00 | |
| Colon cancer | 3.57 | 19.74 | 1.27 | 1.51 | 65.19 | >100 | 1.05 | 0.99 |
| 4.08 | 34.32 | 1.69 | 1.43 | 66.32 | >100 | 1.16 | 1.00 | |
| CNS cancer | 5.42 | 42.23 | 0.84 | 0.71 | 89.98 | >100 | 0.76 | 0.99 |
| 7.31 | 75.70 | 0.94 | 0.65 | 97.50 | >100 | 0.79 | 1.00 | |
| Melanoma | 3.74 | 15.07 | 1.21 | 2.00 | 23.33 | >100 | 2.94 | 0.99 |
| 8.26 | 53.31 | 0.83 | 0.92 | 68.20 | >100 | 1.13 | 1.00 | |
| Ovarian cancer | 5.97 | 46.95 | 0.76 | 0.64 | >100 | >100 | 0.69 | 0.99 |
| 7.07 | 84.65 | 0.97 | 0.58 | 87.14 | >100 | 0.88 | 1.00 | |
| Renal cancer | 3.79 | 17.32 | 1.20 | 1.72 | 71.53 | 88.52 | 0.96 | 1.12 |
| 4.43 | 40.00 | 1.55 | 1.23 | 80.38 | >100 | 0.96 | 1.00 | |
| Prostate cancer | 9.63 | 52.25 | 0.47 | 0.57 | 92.90 | >100 | 0.74 | 0.99 |
| 8.26 | 53.43 | 0.83 | 0.92 | >100 | >100 | 0.77 | 1.00 | |
| Breast cancer | 3.47 | 21.47 | 1.31 | 1.39 | 77.55 | >100 | 0.88 | 0.99 |
| 5.48 | 45.70 | 1.25 | 1.07 | 92.35 | >100 | 0.83 | 1.00 | |
a
repeat assay.